176 related articles for article (PubMed ID: 23054343)
1. "Response to the commentary on "neuromyelitis optica: potential roles for intravenous immunoglobulin"".
Wingerchuk DM
J Clin Immunol; 2013 Feb; 33(2):308. PubMed ID: 23054343
[No Abstract] [Full Text] [Related]
2. Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin.
Bichuetti DB; de Oliveira EM
J Clin Immunol; 2013 Feb; 33(2):307. PubMed ID: 23054342
[No Abstract] [Full Text] [Related]
3. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
4. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
5. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.
Elsone L; Panicker J; Mutch K; Boggild M; Appleton R; Jacob A
Mult Scler; 2014 Apr; 20(4):501-4. PubMed ID: 23986097
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune hepatitis in a patient affected by neuromyelitis optica: a new association.
Romanelli RG; Fassio F; Cappelli F; Giudizi MG; Cecioni I; Matucci A; Castiglione F; Tarquini R; Almerigogna F
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e33-5. PubMed ID: 24070901
[No Abstract] [Full Text] [Related]
7. Neuromyelitis optica presenting as acute bilateral ptosis.
Joshi P; Lanford J; Bourke D
Pract Neurol; 2017 Jan; 17(1):57-59. PubMed ID: 27888234
[TBL] [Abstract][Full Text] [Related]
8. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.
Okada K; Tsuji S; Tanaka K
Intern Med; 2007; 46(19):1671-2. PubMed ID: 17917332
[No Abstract] [Full Text] [Related]
9. Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.
Nobuyoshi S; Kanamori A; Matsumoto Y; Nakamura M
Jpn J Ophthalmol; 2016 Sep; 60(5):419-23. PubMed ID: 27271761
[TBL] [Abstract][Full Text] [Related]
10. Is neuromyelitis optica distinct from multiple sclerosis?: something for "lumpers" and "splitters".
Frohman EM; Kerr D
Arch Neurol; 2007 Jun; 64(6):903-5. PubMed ID: 17562944
[No Abstract] [Full Text] [Related]
11. Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.
Tobin WO; Pittock SJ
JAMA Neurol; 2015 Sep; 72(9):974-7. PubMed ID: 26168370
[No Abstract] [Full Text] [Related]
12. Eculizumab, Neuromyelitis Optica, and Tuberculosis: We Live An Era of Challenging Combinations.
Goncalves MV; Melo LH; Benedet CM; Ribas FD; Cabral NL; Fragoso YD
CNS Neurosci Ther; 2015 Nov; 21(11):914-5. PubMed ID: 26404521
[No Abstract] [Full Text] [Related]
13. Treatment of Corticosteroid Non-responsive Relapse of Neuromyelitis Optica with Intravenous Gamma Globulin - a Case Report.
Dimitrova M; Iliev D
Folia Med (Plovdiv); 2020 Dec; 62(4):861-865. PubMed ID: 33415928
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
15. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica.
Sánchez-Carteyron A; Alarcia R; Ara JR; Martín J
Neurology; 2010 May; 74(18):1471-3. PubMed ID: 20439850
[No Abstract] [Full Text] [Related]
16. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
17. The ethics of placebo controlled clinical trials in NMO - A balance of risks.
Levy M
Mult Scler Relat Disord; 2015 Nov; 4(6):512-4. PubMed ID: 26590656
[No Abstract] [Full Text] [Related]
18. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
19. Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Fuentes Fernandez I; Hernandez-Clares R; Carreón Guarnizo E; Meca Lallana JE
Mult Scler Relat Disord; 2017 Aug; 16():22-23. PubMed ID: 28755680
[TBL] [Abstract][Full Text] [Related]
20. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Capobianco M; Malucchi S; di Sapio A; Gilli F; Sala A; Bottero R; Marnetto F; Doriguzzi Bozzo C; Bertolotto A
Neurol Sci; 2007 Aug; 28(4):209-11. PubMed ID: 17690854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
